Sae2 is required for maintenance of Myc-induced lymphoma in vivo. (A) Eµ-Myc lymphoma cells engineered to express shRNAs targeting Sae2 or a control shRNA as well as GFP were injected (20 000 cells IV) into syngeneic recipients (n = 3 control mice, n = 4 mice for each Sae2 targeting shRNA). Mice were followed for lymphoma onset. Shown is the disease-free survival. (B) After lymphoma onset, mice were euthanized and peripheral blood (PB), bone marrow (BM), lymph nodes (LN), and spleen tissue (SP) were harvested and analyzed for the indicated surface markers using flow cytometry. (C-D) Raji BL cells expressing the ecotropic receptor and rtTA were transduced with a retrovirus expressing Dox-inducible, miR30-based shRNA to silence SAE2 expression. A total of 10 × 106 cells were injected into the flanks of immunocompromised Nod/Scid mice (n = 8). Mice were followed for tumor onset, and a group of 4 mice was treated with Dox to induce the expression of the SAE2 shRNA. (C) FDG-PET imaging of human BL xenografts showing representative images (left) and quantification of metabolic tumor volume by FDG uptake (right) (n = 4 tumors for control, n = 6 tumors from mice treated with Dox). (D) Assessment of xenograft tumor growth (left) and size at end of experiment (right) during a 5-day ±Dox treatment period (n = 6 tumors for control mice, n = 8 tumors from mice treated with Dox).
